decontamin
sd
plasma
guarante
treatment
solvent
deterg
immunolog
neutralis
due
physiolog
presenc
neutralis
antibodi
pool
plasma
fraction
well
doubl
filtrat
remov
cell
cell
fragment
bacteria
sd
treatment
highli
effect
disrupt
lipid
membran
therefor
guarante
high
level
safeti
regard
virus
lipid
envelop
includ
human
immunodefici
viru
hepat
b
c
viru
emerg
one
west
nile
viru
chikungunya
viru
new
influenza
strain
sever
acut
respiratori
syndrom
coronaviru
bacteria
protozoa
intracellular
virus
cytomegaloviru
epsteinbarr
viru
human
cell
leukaemia
viru
ii
addit
treatment
high
reserv
capac
provid
incub
time
fact
reduc
viru
load
detect
level
less
min
sd
process
effect
destroy
log
envelop
virus
vaccinia
viru
rel
resist
pathogen
reduct
techniqu
also
less
effect
nonenvelop
virus
hepat
parvoviru
risk
transmit
infecti
agent
reduc
dilut
initi
viral
load
presenc
neutralis
antibodi
plasma
pool
size
plasma
pool
l
comparison
l
pool
plasmaderiv
medicin
product
produc
hydrophob
chromatographi
product
subject
test
plasma
pool
presenc
genom
materi
concentr
antihepat
antibodi
sd
plasma
time
prophylact
dose
warrant
adequ
protect
infect
concentr
antibodi
parvoviru
similar
intraven
immunoglobulin
use
treat
chronic
infect
transfus
transmiss
report
sd
plasma
outbreak
hepat
occur
factor
viii
product
conclus
preclin
viru
valid
studi
clinic
safeti
virolog
assess
extens
postmarket
clinic
experi
clearli
shown
sd
treatment
achiev
rapid
irrevers
thorough
inactiv
envelop
virus
moreov
efficaci
sd
treatment
highlight
fact
approxim
million
unit
sd
plasma
transfus
without
document
case
transmiss
hbv
hcv
hiv
nevertheless
tradit
sd
pathogen
inactiv
limit
prion
clearanc
capac
abl
reduc
prpsc
log
wherea
extens
remov
capac
log
recent
warrant
mention
modifi
manufactur
process
includ
specif
prion
reduct
step
although
bacteria
rare
contamin
ffp
storag
condit
impact
sd
bacteri
growth
capac
complement
kill
bacteria
recent
investig
show
sd
treatment
plasma
alter
bactericid
activ
complement
inactiv
gramposit
bacteria
dilut
neutralis
antibodi
allergen
industri
process
sd
plasma
pool
reduc
incid
allerg
reaction
recipi
also
result
high
level
final
standardis
concentr
labil
stabl
clot
factor
plasma
protein
thu
elimin
biolog
variabl
singl
unit
ffp
neither
antihuman
leucocyt
antigen
hla
antihuman
neutrophil
antigen
hna
antibodi
detect
sd
plasma
dilut
neutralis
presenc
leukocyt
fragment
remov
sd
treatment
reason
countri
use
sd
ffp
report
transfusionrel
acut
lung
injuri
trali
case
due
transfus
plasma
addit
doubl
filtrat
sd
ffp
remov
residu
cell
mani
fragment
thu
reduc
possibl
alloimmunis
cellmedi
advers
immunolog
reaction
recipi
recent
plasma
sampl
obtain
voluntari
blood
donor
germani
compar
six
aliquot
differ
lot
sd
plasma
tandem
mass
spectrometri
assess
presenc
drug
residu
analys
specimen
residu
diuret
betareceptor
block
agent
stimul
contracept
detect
within
level
commonli
report
case
therapeut
usag
contrari
analysi
aliquot
sd
plasma
prepar
yield
find
drug
residu
result
attribut
dilut
solidphas
extract
includ
industri
product
process
pathogen
inactiv
plasma
method
pathogen
reduct
plasma
current
use
exploit
differ
mechan
action
consequ
gener
larg
quantiti
reactiv
oxygen
speci
ro
ro
key
role
damag
red
blood
cell
recent
foster
approach
improv
qualiti
efficaci
store
red
cell
focus
reduc
oxid
damag
remov
oxygen
begin
storag
maintain
anaerob
state
throughout
storag
period
recent
fey
et
al
reveal
mechan
damag
plasma
constitu
riboflavin
light
show
gener
ro
play
direct
role
advers
affect
biomolecular
integr
relev
plasma
constitu
factor
viii
fibrinogen
case
plasma
product
integr
could
maintain
appli
hypox
condit
pathogen
inactiv
process
import
note
format
singlet
oxygen
upon
illumin
part
mechan
action
also
methylen
blue
mb
pathogen
reduct
system
whose
efficaci
inde
increas
presenc
oxygen
sd
plasma
deriv
ffp
unit
prepar
frozen
optim
collect
product
procedur
moder
reduct
clot
factor
inhibitor
activ
final
composit
similar
ffp
moreov
thank
filtrat
process
high
molecular
weight
multim
von
willebrand
factor
vwf
absent
metalloproteas
implic
pathogenesi
ttp
normal
stabl
h
even
thaw
storag
room
temperatur
sd
plasma
also
contain
normal
level
factor
h
plasma
glycoprotein
involv
control
complement
cascad
pathogen
role
atyp
haemolyt
urem
syndrom
percentag
retent
select
factor
report
tabl
content
factor
viii
lower
compar
sourc
ffp
activ
protein
ps
reduc
reduct
order
magnitud
clinic
signific
due
wide
refer
rang
clot
factor
inhibitor
singl
plasma
unit
level
plasmin
inhibitor
influenc
durat
sd
treatment
size
plasma
pool
qualiti
plasma
rang
normal
valu
sd
plasma
deriv
pool
south
africa
europ
l
increas
french
sd
plasma
deriv
pool
l
approxim
mention
priondeplet
version
sd
plasma
whose
sd
treatment
last
h
less
minipool
plasma
also
activ
ps
less
reduc
normal
howev
evid
support
possibl
role
reduc
level
plasmin
inhibitor
pathogenesi
bleed
hyperfibrinolysi
patient
alter
haemostasi
treat
plasma
fact
europ
retrospect
observ
studi
patient
undergon
orthotop
liver
transplant
reveal
higher
incid
laboratori
sign
hyperfibrinolysi
patient
treat
sd
ffp
treat
ffp
red
cell
transfus
requir
howev
significantli
differ
two
group
patient
hyperfibrinolysi
initi
attribut
reduc
level
sd
ffp
subsequ
correl
amount
bleed
follow
modif
surgic
techniqu
introduct
low
dose
aprotinin
thrombot
haemorrhag
complic
occur
norway
liver
transplant
carri
use
sd
ffp
aprotinin
report
thrombot
haemorrhag
complic
furthermor
descript
persist
bleed
patient
congenit
acquir
defici
plasmin
inhibitor
treat
sd
plasmabas
replac
therapi
therefor
clinic
studi
confirm
initi
concern
due
low
level
antitrypsin
activ
sd
plasma
bleed
problem
liver
transplant
case
report
follow
use
sd
plasma
produc
usa
plasma
may
caus
remark
differ
product
process
north
american
plasma
much
larger
pool
size
less
strict
qualiti
requir
regard
separ
freez
signific
differ
manufactur
process
pla
sd
produc
usa
sd
plasma
product
use
europ
report
differ
includ
way
plasma
obtain
pool
size
ii
citrat
concentr
iii
storag
time
freez
method
sourc
plasma
iii
stabil
plasma
protein
iv
oil
use
extract
solventdeterg
chemic
usa
plasma
deriv
much
larger
pool
l
plasma
obtain
fraction
apheresi
low
citrat
concentr
could
insuffici
avoid
coagul
activ
separ
frozen
h
collect
coagul
factor
stabil
mm
calcium
chlorid
sodium
hydrogen
phosphat
mm
ph
use
european
manufactur
process
furthermor
tnbp
triton
extract
soybean
oil
castor
oil
use
europ
final
pla
sd
underw
concentr
ultrafiltr
passag
use
european
product
therefor
north
american
plasma
show
greater
decreas
activ
antitrypsin
plasmin
inhibitor
activ
plasmin
activ
inhibitor
contain
residu
tnbp
high
concentr
lipoprotein
fibrin
monom
desarg
complement
activ
marker
moreov
american
product
almost
ps
activ
wherea
european
sd
plasma
moder
reduct
ps
activ
antigen
collect
differ
could
respons
advers
effect
report
use
sd
plasma
produc
usa
led
withdraw
market
follow
notif
six
death
caus
thromboembol
complic
orthotop
liver
transplant
three
case
deep
vein
thrombosi
patient
ttp
treat
plasmaexchang
use
sd
plasma
replac
fluid
howev
januari
us
food
drug
administr
approv
sd
plasma
product
manufactur
plasma
collect
us
donor
altern
singledonor
ffp
contrast
europ
report
thromboembol
episod
directli
relat
treatment
sd
plasma
retrospect
analysi
patient
ttp
treat
plasmaexchang
use
sd
plasma
produc
europ
eight
thromboembol
event
found
seven
patient
howev
addit
risk
factor
thrombot
complic
also
describ
use
standard
ffp
plasma
cryosupernat
conclus
thrombosi
hyperfibrinolyt
bleed
trigger
reduc
protein
low
plasmin
inhibitor
potenc
european
sd
plasma
withstood
critic
review
pathogen
reduct
technolog
plasma
current
use
target
nucleic
acid
involv
use
visibl
ultraviolet
light
design
use
blood
establish
exploit
mb
amotosalen
riboflavin
addit
novel
system
exploit
pathogen
inactiv
plasma
platelet
base
shortwav
ultraviolet
c
without
photoact
substanc
current
undergo
clinic
efficaci
safeti
test
detail
descript
product
recent
address
sever
review
articl
tabl
mechan
action
pathogen
reduct
system
plasma
current
use
main
characterist
inactiv
plasma
product
summaris
regard
clinic
use
sd
plasma
congenit
bleed
disord
import
studi
publish
horowitz
pehta
describ
effect
use
sd
plasma
patient
hereditari
defici
factor
ii
v
x
xi
xiii
treat
transfus
episod
activ
bleed
episod
surgic
prophylaxi
episod
routin
prophylaxi
episod
recent
santagostino
colleagu
report
patient
recess
inherit
coagul
disord
afibrinogenemia
factor
v
combin
fv
fviii
factor
x
factor
xi
defici
case
sd
plasma
fulli
effect
remain
three
case
partial
effect
postsurg
mild
bleed
control
continu
increas
treatment
sd
plasma
case
recent
studi
also
recommend
intern
guidelin
appropri
usag
noninactiv
ffp
articl
clearli
show
also
dosag
sd
plasma
use
ensur
effect
treatment
greater
tradit
one
ml
per
kilogram
frequent
approxim
ml
per
kilogram
regard
use
patient
acquir
coagul
deficit
random
doubleblind
studi
assess
abil
sd
plasma
ffp
reduc
prolong
prothrombin
time
pt
less
differ
sd
plasma
ffp
seen
regard
mean
dose
plasma
infus
percentag
patient
correct
pt
sd
plasma
vs
ffp
p
percentag
patient
whose
bleed
stop
sd
plasma
vs
ffp
clinic
respons
plasma
therapi
similar
group
similar
result
found
anoth
random
trial
conduct
beck
et
al
patient
sever
coagulopathi
efficaci
sd
plasma
patient
coagul
defect
associ
liver
diseas
examin
comparison
standard
ffp
prospect
random
trial
fortynin
patient
liver
diseas
undergo
liver
transplant
randomli
assign
receiv
ffp
sd
plasma
prior
procedur
liver
biopsi
transplant
sever
coagulopathi
dose
plasma
infus
similar
group
result
show
correct
clot
factor
level
prolong
activ
partial
thromboplastin
time
aptt
equal
ffp
sd
plasma
greater
decreas
intern
normal
ratio
inr
seen
sd
plasma
group
attribut
author
higher
baselin
inr
patient
compar
ffp
group
notabl
use
sd
plasma
patient
undergo
liver
transplant
increas
need
blood
compon
two
random
trial
analys
use
sd
plasma
patient
undergo
orthotop
liver
transplant
olt
first
studi
freeman
colleagu
patient
coagulopathi
follow
olt
show
equal
correct
sd
plasma
ffp
second
recent
studi
conduct
bindi
colleagu
olt
patient
use
sd
plasma
associ
monitor
haemostasi
mean
thromboelastographi
gave
therapeut
result
ffp
signific
reduct
amount
plasma
transfus
ml
ffp
group
vs
ml
sd
plasma
group
p
similar
find
ml
ffp
group
vs
ml
sd
plasma
group
emerg
also
studi
conduct
group
critic
ill
patient
regard
use
sd
plasma
patient
complex
coagulopathi
associ
cardiac
surgeri
prospect
trial
found
patient
treat
ml
sd
plasma
show
similar
rise
factor
viii
fibrinogen
antithrombin
protein
c
free
ps
antitrypsin
plasminogen
well
decreas
pt
aptt
compar
patient
treat
ml
ffp
hand
signific
differ
product
found
level
total
ps
plasmin
inhibitor
howev
clinic
haemostasi
evalu
reveal
signific
differ
two
treatment
regimen
result
agreement
previou
find
random
clinic
trial
conduct
wied
et
al
compar
sd
plasma
mb
light
virusinactiv
plasma
patient
undergo
cardiopulmonari
bypass
surgeri
prospect
random
studi
tollofrsud
et
al
also
report
posit
experi
use
sd
plasma
openheart
surgeri
final
basi
find
sd
plasma
lack
highest
molecular
weight
vwf
multim
involv
pathogenesi
ttp
investig
assess
sd
plasma
treatment
patient
acut
ttp
report
rate
remiss
furthermor
studi
document
sd
plasma
dramat
reduc
even
elimin
allerg
reaction
sd
plasma
withdrawn
us
market
year
ago
recent
reintroduc
europ
continu
wide
util
laboratori
evid
markedli
differ
composit
us
product
studi
fail
detect
thrombot
complic
similar
patient
group
inde
haemovigil
nation
program
clearli
demonstr
safeti
sd
plasma
clinic
set
clinic
experi
franc
transfus
million
unit
sd
plasma
sinc
finland
unit
sinc
show
signific
reduct
rate
seriou
advers
event
approxim
compar
standard
ffp
sinc
norway
unit
sd
plasma
success
transfus
categori
patient
includ
neonat
liver
transplant
patient
case
transmiss
viral
diseas
thrombot
complic
trali
similar
find
emerg
belgian
retrospect
analysi
sd
plasma
unit
transfus
recipi
uk
unit
sd
plasma
transfus
introduct
seriou
hazard
transfus
shot
haemovigil
system
without
report
seriou
problem
support
data
also
provid
austrian
haemovigil
registri
report
allerg
reaction
ffp
sd
plasma
italian
haemovigil
registri
report
significantli
lower
rate
advers
reaction
sd
plasma
compar
nonpharmaceut
ffp
advers
reactionsunit
plasmasaf
kedrion
spa
castelvecchio
pascoli
lucca
itali
vs
ffp
p
follow
transfus
unit
avail
system
inactiv
pathogen
ffp
clinic
use
rais
question
whether
extent
treatment
notori
use
reduc
risk
posttransfus
infect
introduc
current
level
transfus
safeti
make
costbenefit
ratio
introduc
use
pathogeninactiv
ffp
unfavour
even
econom
develop
countri
benefit
measur
relat
residu
risk
infect
first
costeffect
analysi
sdtreat
plasma
publish
aubuchon
birkmey
conclud
public
health
perspect
rel
high
cost
small
benefit
reduc
envelop
viru
infect
risk
sd
plasma
addit
risk
nonenvelop
viru
transmiss
appear
justifi
widespread
implement
technolog
anoth
two
studi
assess
costeffect
sd
plasma
three
studi
yield
wide
rang
costqualityadjust
life
year
qali
estim
conclud
increas
level
safeti
sd
plasma
justifi
consider
addit
cost
howev
studi
consid
sever
rel
common
noninfect
transfusionrel
complic
greatli
underestim
costeffect
blood
compon
riedler
cowork
consid
variou
infect
noninfect
transfusionrel
complic
trali
sd
plasma
prove
costeffect
treatment
patient
age
cost
per
lifeyear
save
remain
older
patient
good
clinic
prognosi
van
eerd
et
al
confirm
costeffect
sd
plasma
also
critic
ill
patient
analysi
base
model
structur
origin
develop
canadian
agenc
drug
technolog
health
cadth
howev
differ
cadth
studi
highlight
increment
cost
per
qali
gain
increment
cost
per
lifeyear
save
also
includ
sever
allerg
reaction
costutil
analysi
model
treatment
inactiv
plasma
result
qali
lifeyear
save
compar
ffp
pathogenreduc
plasma
consid
costeffect
threshold
per
qali
latest
publish
costeffect
budget
impact
studi
includ
risk
sever
allerg
reaction
bacteri
infect
prion
diseas
two
unknown
virus
analysi
sd
plasma
result
qali
gain
comparison
ffp
probabl
costeffect
ca
per
qali
threshold
greater
therefor
consid
cost
save
also
abl
provid
addit
benefit
term
safeti
comparison
ffp
current
standard
care
conclus
costeffect
analys
relat
cost
programmetechniqu
key
outcom
benefit
deem
project
benefit
sd
plasma
usag
also
includ
eliminationreduct
complic
trali
sever
allerg
reaction
well
prevent
complic
caus
emergingunknown
infecti
agent
comput
costeffect
ratio
realli
abl
support
robust
recommend
aim
includ
therapeut
tool
current
standard
care
sd
plasma
pharmaceut
product
standardis
content
clot
factor
devoid
antibodi
implic
trali
pathogenesi
high
level
decontamin
transfusiontransmiss
infecti
agent
product
thirti
year
mani
clinic
studi
confirm
efficaci
congenit
acquir
bleed
disord
sever
costeffect
analys
show
use
justifi
decreas
health
care
expens
plasma
transfus
improv
alreadi
high
level
transfus
safeti
